Loading...
XNAS
AXGN
Market cap1.53bUSD
Dec 05, Last price  
33.32USD
1D
1.42%
1Q
108.51%
Jan 2017
270.22%
Name

AxoGen Inc

Chart & Performance

D1W1MN
XNAS:AXGN chart
P/E
P/S
8.18
EPS
Div Yield, %
Shrs. gr., 5y
2.44%
Rev. gr., 5y
11.91%
Revenues
187m
+17.81%
443,352126,660100,43172,71124,911,37691,2734,849,4707,691,70410,947,36116,817,40327,331,09241,107,53860,426,39583,937,000106,712,000112,300,000127,358,000138,584,000159,012,000187,338,000
Net income
-10m
L-54.12%
-530,612-367,182-748,980-1,040,70915,046,332-1,316,299-9,219,220-9,417,958-14,556,885-17,710,476-13,356,425-14,411,144-10,445,462-22,397,000-29,122,000-24,802,000-28,063,000-27,335,000-21,716,000-9,964,000
CFO
5m
P
-709,618-28,793-466,947-470,16415,441,941-2,429,661-7,079,290-8,661,858-10,444,758-10,451,059-13,051,819-11,204,442-9,237,599-17,862,000-19,872,000-9,626,000-13,405,000-16,066,000-5,716,0004,535,000
Dividend
Jan 27, 20101 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
IPO date
Dec 17, 1986
Employees
394
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT